Rasagiline Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0012 
Minor change in labelling or package leaflet not 
22/02/2023 
connected with the SPC (Art. 61.3 Notification) 
N/0011 
Minor change in labelling or package leaflet not 
18/10/2022 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IB/0010 
B.II.b.5.f - Change to in-process tests or limits 
22/03/2022 
n/a 
applied during the manufacture of the finished 
product - Addition or replacement of an in-process 
test as a result of a safety or quality issue 
T/0009 
Transfer of Marketing Authorisation 
24/09/2021 
19/10/2021 
SmPC, 
Labelling and 
PL 
IB/0008/G 
This was an application for a group of variations. 
08/10/2021 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.z - Quality change - Active substance - Other 
variation 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/07/2021 
19/10/2021 
SmPC and PL 
To update section 4.4 of the SmPC and section 2 and 4 of 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the PL to align adverse effects based on the Brand Leader's 
text. 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
R/0006 
Renewal of the marketing authorisation. 
17/09/2020 
20/11/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Rasagiline Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
N/0004 
Minor change in labelling or package leaflet not 
24/04/2020 
20/11/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0005/G 
This was an application for a group of variations. 
10/04/2020 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
N/0003 
Minor change in labelling or package leaflet not 
24/01/2019 
20/11/2020 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0002 
A.5.b - Administrative change - Change in the name 
15/09/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0001/G 
This was an application for a group of variations. 
18/05/2016 
08/05/2017 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
PL 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 4/4 
 
 
 
 
 
 
 
